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 Abstract 
Identifying whether potential causal variants for related diseases are shared 
can identify overlapping etiologies of multifactorial disorders. Colocalization 
methods disentangle shared and distinct causal variants. However, existing 
approaches require independent datasets. Here we extend two colocalization 
methods to allow for the shared control design commonly used in comparison 
of genome-wide association study results across diseases. Our analysis of 
four autoimmune diseases, type 1 diabetes (T1D), rheumatoid arthritis, celiac 
disease and multiple sclerosis, revealed 90 regions that were associated with 
at least one disease, 33 (37%) of which with two or more disorders. 
Nevertheless, for 14 of these 33 shared regions there was evidence that causal 
variants differed. We identified novel disease associations in 11 regions 
previously associated with one or more of the other three disorders. Four of 
eight T1D-specific regions contained known type 2 diabetes candidate genes: 
COBL, GLIS3, RNLS and BCAR1, suggesting a shared cellular etiology. 
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 Introduction 
Overlaps of genetic association to different diseases have been widely observed, 
and are thought to reflect shared etiology between diseases.1 However, showing that 
a variant is associated with two traits does not demonstrate that it is causal for both: 
this may be due to distinct variants in linkage disequilibrium.2 Colocalization 
analyses are used to study whether potential causal variants are shared by 
combining information across multiple single nucleotide polymorphisms (SNPs) in a 
region. The proportional approach3 tests a null hypothesis of proportionality under 
which, if causal variants are shared, we expect to see that the effects of any set of 
SNPs on the two diseases are proportional to each other. A weakness of this 
approach is interpretation. Failure to reject the null hypothesis does not only imply 
colocalization, but could also be caused by either disease being not associated, or 
by insufficient power owing to too few samples analysed and/or an incomplete 
genetic map4 (Supplementary Fig. 1). We have no way of measuring how likely 
colocalization is. A strength is that no assumptions are made about the number of 
causal variants: the null hypothesis corresponds to complete sharing across all 
causal variants. An alternative is to use a Bayesian framework,5 to generate 
posterior probabilities for colocalization and distinct causal variants, as competing 
hypotheses. However, a weakness of this approach, as currently developed, is that it 
assumes only a single causal variant for each trait within any region.  
Existing colocalization methods require that genetic association with the two traits 
of interest has been tested in distinct samples. However, this requirement restricts 
the applicability of the approach to related diseases since each set of case samples 
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must have a corresponding distinct set of control samples, enabling a logistic 
binomial model to be used independently upon each disease. In contrast, many 
studies use a common set of controls for different diseases to increase efficiency. 
Here, we extend both colocalization methods to allow for the use of multinomial 
logistic regression, the natural model for shared controls.  
Previous studies have identified many regions associated with multiple 
autoimmune or autoinflammatory diseases, including type 1 diabetes (T1D) and 
celiac disease (CEL).6,1 Such multi–disease association led to the development of 
the ImmunoChip,7 a custom genotyping chip with 196,000 SNPs designed to densely 
cover 186 regions known to associate with at least one immune disease on the basis 
of GWAS p–value < 10–8. The ImmunoChip consortium genotyped a common control 
set, to which some disease groups added their own controls. We applied our 
extended methods to ImmunoChip raw genotyping data for a total of 36,030 
samples, including one set of controls and four disease cohorts, in order to better 
understand the extent of shared genetic etiology in these diseases.  
Results 
Overview of Method 
The Bayesian method derives the posterior support for each of five hypotheses 
describing the possible association of the region with both diseases. Of greatest 
interest are: 
ℍ3: Both diseases are associated with the region, with different causal variants. 
ℍ4: Both diseases are associated with the region, and share a single causal variant. 
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Association with both traits corresponds to ℍ3 or ℍ4; colocalization corresponds to 
ℍ4. This method requires specification of prior probabilities for each hypothesis. We 
calibrated priors to match our expectations that about 50% of regions associated 
with two immune–mediated diseases correspond to a shared causal variant 
(Supplementary Fig. 2), which is close to the proportion found in a manually curated 
summary of association to six immune–mediated diseases8 (58%). For rheumatoid 
arthritis (RA)9 and multiple sclerosis (MS),10 for which only UK subsets of 
international cohorts were analyzed, we modified priors in regions with published 
associations to reflect this additional information from the published papers. Where a 
region was annotated in ImmunoBase as associated with RA or MS, we shrunk our 
priors for hypotheses corresponding to no association for the disease close towards 
0, and increased our priors for the remaining hypotheses (Supplementary Methods).  
One hundred and twenty six ImmunoChip regions assigned to at least one of the 
diseases (based upon knowledge when the chip was designed or identified in 
subsequent papers and curated in ImmunoBase, accessed 12/11/13) were analyzed 
using both approaches for all six pairwise comparisons of the four diseases. Sample 
and SNP QC is described in the Methods; we excluded low frequency variants 
(MAF< 1%) to reduce the number of models to be considered and because 
genotyping errors are more common amongst this group of SNPs, and we did not 
have cluster plots available for all diseases. Although GWAS studies typically have 
sufficient power to detect association only with more common SNPs, some rarer 
variants (for example, in TYK211) have been reported with these diseases which will 
be missed in our analysis.  
Overview of Results 
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The Bayesian approach assumes a single causal variant per trait in any region. 
To allow for multiple causal variants, we used a stepwise method. In the 
overwhelming majority of cases (740 out of 756 pairwise comparisons, or 98%) data 
were consistent with at most one causal variant per trait in a region. Ninety of the 
126 regions (71%) showed association with at least one disease; in 33 regions, the 
association was shared between at least two diseases (Fig 1). Complete results are 
given in Supplementary Table 1, Supplementary Table 2 and Supplementary Table 
3. For fifty–seven regions, the greatest support was for association with precisely 
one of the four diseases; in 21 cases, we know of no other immune–mediated 
diseases that have reported association to these regions and therefore hypothesize 
these may be disease specific among autoimmune diseases (Table 1).  
In the Bayesian approach, when the posterior probability of a hypothesis is close 
to 0.5, assignment cannot be made with confidence to any single hypothesis. 
However, in the 30 instances in which both diseases showed very strong evidence of 
association (ℙ(ℍ3 or ℍ4) > 0.9), the Bayesian and proportional approaches produced 
consistent results. For these 30 cases, the proportional null was rejected only in 
cases in which the Bayesian analysis favored ℍ3, and not rejected in cases where 
ℍ4 was favored. Focusing on these, the data strongly supported that the same 
causal variants underlie all diseases in ten cases, while seven showed strong 
evidence for distinct variants, suggesting that just under half, 42%, of overlapping 
association signals reflect distinct causal variants. In total, fourteen regions showed 
evidence of separate SNP effects (ℙ(ℍ3) > 0.5, see Table 2). 
Disentangling Patterns of Association 
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For colocalized disease regions, the two diseases generally have consistent 
directions of effect (Fig 2) with the exception of the 6q25.3 region containing 
candidate gene TAGAP, which is associated in our analysis with CEL and MS only: 
the risk allele for CEL is protective for MS and vice versa (Supplementary Fig. 3). 
This opposing effect of TAGAP alleles has been previously described for T1D and 
CEL,6 although the region did not provide sufficient evidence for association with 
T1D in the data available to us. A similar effect for the 2q12.1 region containing 
candidate gene IL18RAP has also been reported.6 However, later data12 have not 
offered support for T1D association to 2q12.1, and, in our analysis, the posterior 
support is concentrated on CEL association alone.  
Patterns of association with multiple diseases can be complex. In the 2q33 region 
containing established candidate gene CTLA4, as well as the equally strong 
functional candidate genes, CD28 and ICOS, three potential causal variants appear 
to be partially shared between T1D, RA and CEL. The strongest association with 
T1D is at rs3087243 (which has previously been called CT60), while the strongest 
association with CEL is with rs231775 (which alters the amino acid at position 17 of 
CTLA4, Ala17Thr, and has previously been called CT42). The two SNPs have r2 = 
0.5, and haplotype analysis has previously suggested CT60 and not CT42 is causal 
for Graves’ disease.13 For RA, the strongest single SNP signal is at rs1980422, 
which is not in LD with either CT42 or CT60 (r2 < 0.1). We fitted the 512 possible 
standard multinomial models involving these three SNPs for the three diseases, and 
computed approximate Bayes factors for each. Assuming each model to be equally 
likely a priori, the model with highest posterior probability has rs1980422/rs3087243 
(CT60) signals for CEL and rs231775 (CT42)/rs1980422 for both T1D and RA, 
although whilst rs231775 (CT42) is the strongest effect for T1D, rs1980422 is 
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strongest for RA (Fig. 3). We note that our analysis is based on SNPs selected 
through a stepwise process and that without fine mapping analysis we cannot claim 
that any one of these models correctly reflects the causal variants for any disease.  
These results do, however, clearly illustrate the different patterns of association with 
the three disorders and emphasize the potential complexity that can arise in regions 
of multiple association signals.  They motivate the future extension of the 
colocalization approach developed here to allow model search strategies that do not 
require stepwise assumptions. 
Discovery of Novel Associations 
Two regions were associated with all four diseases (Fig. 1). One was the 6q23.3 
region containing candidate gene TNFAIP3, known to be associated with RA and 
CEL. There has been some published evidence that T1D is associated with this 
region,14 although not at genome–wide significant levels. Our results identify a T1D 
signal, colocalized with that for RA and CEL, suggesting a single shared causal 
variant affecting the three diseases. There is also evidence of MS association, driven 
by a distinct causal variant (in the CEL–MS analysis, ℙ(ℍ3) = 0.83, Fig. 4).  
The second region was 19p13.2, known to be associated with T1D, RA and MS, 
containing the strong functional candidate gene TYK2, although immune adhesion 
genes ICAM1 and ICAM3 are also good candidate genes. Our analysis supports 
these associations, with a posterior probability of colocalization approaching 1. We 
also find evidence for a novel CEL association. In each of the pairwise analyses 
involving CEL, the probability of both diseases being associated ≃ 0.88, although 
this could be a distinct signal: we have ℙ(ℍ4|ℍ3 or ℍ4) ≃ 0.5 (Supplementary Fig. 4). 
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In total, 11 regions showed strong evidence of novel association with ℙ(ℍ3 or ℍ4) > 
0.5 (Table 3).  
In regions with colocalizing novel associations, effect sizes tended to be smaller 
in the new disease (Fig. 2). This could indicate that the stronger effect is in the 
previously known association, or it could be due to Winner’s Curse,15 with the 
previously known associations displaying inflated effect size estimates. In general for 
colocalized signals, the coefficient of proportionality is centered about 1.  
One novel association found was in the chromosome 1q24.3 region, known to be 
associated with CEL and containing candidate gene FASLG. Pathway analysis also 
produced evidence for a T1D–associated variant here,16 although no SNP has 
reached the genome–wide significance threshold. Our results support a shared 
causal variant for T1D and CEL (posterior probability 0.71). Our Bayesian approach 
also enables fine–mapping when dense genotyping data are available, as is the case 
here. We identified a single likely causal variant lying in a region with strong 
evidence of predicted regulatory activity, rs78037977 (Supplementary Fig. 5), with a 
posterior probability of being causal amongst all genotyped variants, given the 
colocalization hypothesis, of 0.99. Note that rs78037977 was removed from the CEL 
data in the original analysis17 owing to failing a missingness check (the call rate of 
99.942% was just below the 99.95% cut–off). Plots of the signal clouds for our 
samples at this SNP are given in Supplementary Figure 6. The clustering shown 
here is of good quality, implying that the rs78037977 genotype can be considered 
reliable.  
Prior Sensitivity 
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We tested prior sensitivity by varying p12 (the probability that an arbitrary SNP is 
associated with both diseases) from p12 = 10–5 to 10–7, while keeping p1 and p2 (the 
probability that this SNP is associated with only trait 1, or only trait 2) constant at 10–
4 (Supplementary Table 4). Whether a region is disease specific is largely unaffected 
by choice of p12 and, for the five regions discussed in detail in this paper 
(1q24.3/FASLG; 2q33.1/CTLA4; 6q23.3/TNFAIP3; 6q25.3/TAGAP and 
19p13.2/TYK2), the prior does not change which diseases are associated. However, 
the posterior odds for ℍ4:ℍ3 does vary with p12. Under p12 = 10–7, neither 
1q24.3/FASLG nor 6q23.3/TNFAIP3 had strong posterior support as a novel T1D 
region since the evidence for novel association in these regions comes about due to 
colocalization with the stronger previously known association. This dependence on 
prior belief is a strength of Bayesian methods, but they require that priors be 
carefully calibrated. Whilst our prior belief is that about 50% of regions associated 
with two immune–mediated diseases are likely to correspond to a shared causal 
variant, others may disagree. The results given in Supplementary Table 2 can be 
used to calculate the posterior under any alternative p12 using the formula given in 
Supplementary Material.  
Discussion 
Colocalization methods so far have allowed for the simultaneous analysis of only two 
traits: a potential weakness when considering more than two diseases, as 
investigated here. The Bayesian approach could be extended to arbitrarily many 
traits, at the cost of increased computational complexity and spreading the posterior 
over an exponentially increasing hypothesis space, potentially making it difficult to 
draw firm conclusions. Wen et al, in their description of an alternative method for 
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partitioning the association of a single SNP amongst multiple related quantitative 
traits,18 suggest dealing with this complexity by considering only the extremes – a 
SNP is associated to all traits, exactly one, or none. Such reduction is impractical 
when analyzing regions, since it does not allow for overlapping but distinct signals. 
Although we have extended our software to consider three diseases simultaneously, 
we have chosen for practical reasons to focus on pairwise analyses with manual 
curation of the 11 cases (9%) for which more than two diseases showed association.  
Giambartolomei et al5 showed that inference is consistent when the causal 
variant is directly genotyped or well imputed. The decision was taken when the 
ImmunoChip was designed not to thin by LD, but instead target all SNPs and small 
indels known at that time in 1000 Genomes European samples and it has since been 
shown that common variants may be very accurately imputed using ImmunoChip.19 
Therefore we are likely to be very close to the situation where causal variants are 
directly genotyped. The application of our method to the less complete coverage 
provided by genome–wide SNP arrays would require an imputation step to allow 
consistent inference to be made. The Bayesian colocalization analysis assumes a 
single causal variant per region, which could be restrictive, and we addressed this 
using a stepwise approach, attempting to colocalize the individual signals for each 
disease where there was evidence for more than one. The agreement between our 
results with this approach and using the proportional colocalization approach which 
does not make this assumption confirms the appropriateness of the stepwise 
approach in the cases we consider.  
We identified 21 regions that appeared associated to only one autoimmune 
disease. One challenge in interpretation when defining disease unique signals is 
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exemplified by a region on chromosome 7p12.2 which contains the candidate causal 
gene IKZF1. This gene overlaps two ImmunoChip regions separated by a 
recombination hotspot, one 5’ of IKZF1 and one 3’ of IKZF1. The 5’ region contains a 
colocalized signal for MS and T1D, whilst the 3’ region contains only a T1D signal 
(Supplementary Fig. 7). Our analysis has been based on regions, as defined in the 
design of the ImmunoChip and based on recombination hot spots. However, whilst 
the T1D signals in these regions are independent and the 3’ region of IKZF1 appears 
unique to T1D, it is plausible that the causal variants in both regions act through the 
same gene, IKZF1. Another challenge is to deal with the effects of power, given the 
established influence of sample size on power to detect associations.20 Many of the 
regions in Table 1 contain genes linked to immune function, and we expect a number 
of apparent disease–specific results to associate with other diseases as sample 
sizes for each disease continue to increase. Indeed, the chromosome 19p13.11 
region, associated only with MS in our analysis, has previously been associated with 
lymphocyte count,21 with high LD between the peak MS SNP (rs1870071) and the 
lymphocyte count SNP (rs11878602, r2 = 0.99), suggesting an immune mechanism 
for the association.  
However, in the case of T1D, three disease–unique regions overlap known type 2 
diabetes (T2D) regions. Chromosome 9p24.2, containing the candidate gene GLIS3, 
has been associated with T2D22 and fasting glucose23 with high LD between the 
peak SNP for T1D (rs10814914) and these other traits (rs7041847, r2 > 0.9). GLIS3 
and its causal allele alter disease risk by altering pancreatic beta–cell function, 
probably by increasing beta–cell apoptosis.24 Chromosome 16q23.1, containing the 
candidate gene BCAR1, is associated with T1D in our analysis and T2D,22 and the 
T2D alleles in this region have been associated with reduced beta cell function,25 
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again with high LD between the peak SNPs for T1D (rs8056814) and T2D 
(rs7202877, r2 = 0.81). Inspecting the distribution of T2D GWAS p values at the peak 
SNPs in our T1D associated regions (Supplementary Fig. 8), we note that the peak 
SNP in the T1D associated region 6q22.32, rs17754780, also shows association to 
T2D (p = 7.9 × 10–5) and is in tight LD with peak T2D SNP in the region (rs9385400, 
r2 = 0.97). This region has been reported as associated with T2D at genome–wide 
significance in a larger study.26 Chromosome 6q22.3 is not uniquely associated to 
T1D in our analysis because it overlaps an established Crohn’s disease region,27 but 
the lead Crohn’s SNP (rs9491697) is not in LD with the T1D SNP (r2 = 0.03). This is 
then likely to be a third shared signal between T1D and T2D. The nearest genes are 
MIR588 about which little appears to be known and CENPW (centromere protein W) 
which has no obvious functional candidacy. This genetic overlap between T1D and 
T2D (Supplementary Table 5) emphasizes that T1D results from an interaction 
between the immune system and beta cells, and it is probable that some of our other 
apparent disease unique regions will also prove to be specific to the target of 
autoimmune destruction in MS and RA.  
By analyzing regions known to associate with one disease, we were able to link 
11 to additional disorders: in most cases (8/11) the novel disease association was 
clearly colocalized with a previously known signal, whilst in one case, GPR183, the 
evidence supported a distinct causal variant for the novel association. In others 
(3/11) the evidence for colocalization was more equivocal, even with evidence for 
pairwise association.  
In a standard GWAS analysis, a p–value significance threshold of 5 × 10–8 is 
used in absence of replication data, due to a desire to minimise reporting of false 
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positive results, although a relaxation of this threshold has been suggested.29 
However, since autoimmune diseases are known to share etiology, conditioning 
upon association for one autoimmune disease, we should require a less stringent 
threshold to believe it significant for another. Indeed, whilst the question of whether 
the ImmunoChip significance threshold should be somewhat relaxed remains,8 
examination of p–values in the regions in which we observe novel associations 
(Supplementary Fig. 9) suggests that a threshold between 10–5 and 10–6 for SNPs 
that are confirmed index SNPs for another disease might be more appropriate. We 
estimated that 42% of overlapping and genome–wide significant immune–mediated 
disease signals relate to distinct causal variants. In these regions, therefore, there 
appear to be distinct causal variants for two or more autoimmune diseases which are 
physically proximal but in low LD. We suggest that physical proximity to a known 
associated variant in a related disease, and not only LD with it, may prove to be an 
appropriate criterion with which to alter interpretation of a small but not genome–
wide significance threshold. Variants meeting such thresholds might be prioritised for 
genotyping in replication samples. We note, also, that the four diseases we studied 
are all characterized by the presence of autoantibodies. Had we included 
autoantibody negative diseases we might have found a higher proportion of 
discordant associations as reported in a previous manual curation of ImmunoChip 
studies,8 given there remains considerable overlap in location of association signals. 
Although a careful and detailed manual curation of several studies has been 
conducted,8 the ability of colocalization methods to distinguish shared from distinct 
causal variants allows clearer interpretation of genetic results.  
In summary, we have developed a methodology for examining shared genetic 
etiology between diseases in the case of common control datasets, extending 
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previous work.2,3 This enables the discovery of new disease associations and the 
exploration of complex association patterns. Although these methods have been 
presented in this paper to analyze autoimmune diseases, the prior is user defined, 
and could be used to analyze any pair of related diseases.  
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Figure Legends 
 
Figure 1: A Venn diagram showing summary of disease assignments to 90 regions 
which showed association to at least one disease, based upon the results of the 
Bayesian analysis. In cases where assignment was uncertain, the assignment most 
supported by the posterior probabilities was used. The numbers in brackets 
correspond to how many of these regions show evidence of distinct causal variants. 
Thirty–six regions analyzed did not demonstrate association to any disease within 
our available data, and so are not included in this figure. 
 
Figure 2: The distribution of η�, the estimated proportionality coefficient, together with its 
95% confidence interval. In the case of colocalization, η is the ratio of the effects the 
region exert upon the two traits. |η| > 1 corresponds to a stronger effect in Trait 2 
than Trait 1. We estimate η by η�. Labels on the x–axis give the traits and regions 
analyzed; D for T1D, R for RA, C for CEL and M for MS. Note that in some regions, 
the conditional analysis supports the existence of multiple associated variants: if 
none of these overlap, then we consider the region to have separate SNP effects.  
(a) Regions with strong evidence of colocalization (ℙ(ℍ4) > 0.9). As we would 
expect, η� is distributed about 1, which corresponds to the regions having 
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equal effects on each trait. Note that 6q25.3, containing the candidate causal 
gene TAGAP, has η�< 0, indicating opposite effects on the two diseases. Trait 
1 is listed first, and trait 2 second.  
(b) Regions with novel evidence of disease association, in which we believe 
there to be colocalization present between the novel association and at least 
one of the existing associations. Regions have been ordered such that 
η� estimates the effect size for the novel trait divided by the effect size for the 
known association. Labels give the novel association being given first. It can 
be seen that the effect size tends to be smaller in the new disease. 
 
 
 
Figure 3:  The 2q33.1 region containing the candidate gene CTLA4. Three potential 
causal variants are partially shared between T1D, RA and CEL. 
 
(a) A Manhattan plot of the region. The blue signal corresponds to the tag rs231775, the 
green to rs1980422 and the magenta to rs3087243. All other SNPs are colored 
according to their linkage disequilibrium with these three SNPs. SNPs rs231775 and 
rs3087243 have r2 = 0.50; all other pairwise r2 < 0.1.  
(b) Each possible model involving these three SNPs was tested; the four models with 
highest posterior probabilities, which together encompass over 90% of the total 
posterior probability, are shown.  
(c) Effect size estimates (including 95% confidence intervals) of each SNP for each 
disease for the most likely model. 
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(d) Effect size estimates (including 95% confidence intervals) of each SNP for each 
disease for the second most likely model. 
 
Figure 4: The 6q23.3 region containing candidate causal gene TNFAIP3. Our results 
show that T1D, RA and CEL all colocalize, suggesting a single shared causal variant 
affecting the three diseases; rs6933404 being the most likely SNP. There is also 
evidence of MS association, driven by a distinct causal variant. Note that this region 
was associated with MS at genome–wide significant levels in the analysis of the 
international MS dataset10. 
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Tables 
 
     
Chromosome  Position  Disease Association  Posterior Probability of Single Association  Candidate Causal Gene(s)/ Genes in Region  
     
     
1p22.1  92023171–93311800 MS  1.00  EVI5  
     
1p21.2  100982239–101455699  MS  0.57  EXTL2 VCAM1 SLC30A7  
     
1p13.1  116831830–116911865  MS  1.00  CD58  
     
3p24.1  28015774–28105476 MS  0.99  (CMC1)  
     
3q13.33  122818149–123329522  MS  1.00  IQCB1 SLC15A2 CD86  
     
5q21.1  102062861–102777130  RA  0.58  C5orf30  
     
6q23.3  137348296–137587799  MS  1.00  IL22RA2  
     
7p12.2  50337180–50662811 T1D  0.97  3’ IKZF1* region  
     
7p12.2  50866661–51640000 T1D  1.00  COBL  
     
8q21.12  79575897–79914680 MS  1.00  ZC2HC1A  
     
8q24.21  129187117–129368419  MS  0.51  PVT1 MIR1208  
     
9p24.2  4218549–4311558  T1D  1.00  GLIS3  
     
10q23.31  89998026–90268360 T1D  0.87  RNLS  
     
11p15.5  2024999–2264880  T1D  1.00  INS  
     
12q24.31  121926103–122574026  MS  0.59  PITPNM2  
     
14q32.2  100357783–100398492  T1D  0.98  DLK1  
     
16q23.1  73760230–74086012 T1D  1.00  BCAR1  
     
19p13.3  6564831–6636304  MS  1.00  TNFSF14  
     
19p13.11  16300497–16612240 MS  1.00  (EPS15L1, CALR3, MED26, C19orf44, CHERP, SLC35E1)  
     
19p13.11  17905598–18272802 MS  0.87  MPV17L2 IFI30  
     
20p13  1444472–1707590  T1D  0.99  (SIRPD, SIRPB1, SIRPG)  
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    Table 1: Twenty–one regions which are most likely disease specific under our analysis 
and for which we know of no other immune–mediated diseases (from the 15 
diseases curated in ImmunoBase) that have reported association to these regions 
(as curated in ImmunoBase, accessed July 9th 2014, and NIHR GWAS catalog, 
accessed 07/10/2014). Regions required posterior probability of single disease 
association > 0.5 in at least one pairwise analysis (SNP coverage varies between 
analyses) and posterior probability of association to any other disorder < 0.2. 
Candidate causal genes are given. In the case where no candidate causal genes are 
known, we have given, in brackets, the genes in and around the region. *There are 
two ImmunoChip regions which overlap IKZF1 and are separated by a recombination 
hotspot. The region towards the 5’ end has colocalizing associations with MS and 
T1D while the region towards the 3’ end appears specific to T1D, as shown in 
Supplementary Figure 7. Note we provide coordinates of the region, and not an 
index SNP as is conventional in gwas studies because the method synthesises 
information across the whole region and does not, in most cases, highlight a single 
SNP responsible for the association. 
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Chromosome  Position  Associations  Evidence  Candidate Causal Gene  
       
      
2p16.1  60722116–61952276 C—M  CM:ℍ3 ~0.65  REL  
       2q32.2  191412527–191739472  RC—M  RM:ℍ3 ~0.51  STAT1 STAT4  
       2q33.1  202920548–204528303  D—C—R  DR:ℍ3 ~0.98 RC:ℍ3 ~0.91  CD28 CTLA4 ICOS  
       3p21.31  45812888–46633741 D—C  DC:ℍ3 ~0.92  CCR3 CCR1 CCR5  
       3q25.33  160950948–161389020  C—M  CM:ℍ3 ~0.96  IL12A  
       4q27  123121079–124497235  D—C  DC:ℍ3 ~1.00  IL2 IL21  
       6q23.3  137914792–138345363  DRC—M  RM:ℍ3 ~0.75 CM:ℍ3 ~0.85  TNFAIP3  
       10p15.1  6068495–6237542  D—M  DM:ℍ3 ~1.00  IL2RA  
       11q23.3  117805448–118403529  C—M  CM:ℍ3 ~0.82  CXCR5  
       13q32.3  98723872–99034738 D—C  DC:ℍ3 ~0.67  GPR183  
       16p13.13  10831557–11408130 DM—C  DC:ℍ3 ~0.51  DEXI SOCS1  
       18p11.21  12407903–12919721 D—C  DC:ℍ3 ~0.58  PTPN2  
       19p13.2  10081000–11019034 DRM—C  DC:ℍ3 ~0.53  ICAM1 ICAM3 TYK2  
       21q22.3  42681877–42771181 D—R—C  DR:ℍ3 ~0.77 DC:ℍ3 ~0.99 RC:ℍ3 ~0.69  UBASH3A  
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 Table 2: Fourteen regions showing evidence of separate SNP effects (ℙ(ℍ3) > 0.5). D 
corresponds to T1D, R to RA, C to CEL and M to MS. Candidate causal genes are 
as associated across all curated diseases by ImmunoBase. Distinct signals are 
indicated by ‘— ’. Many of these regions are associated with other diseases (see 
ImmunoBase). For instance, the 2q32.2 region is additionally associated with 
Ulcerative Colitis, Crohn’s Disease, Primary Biliary Cirrhosis, Systemic Lupus 
Erythematosus and Juvenile Idiopathic Arthritis. The 6q23.3 region is additionally 
associated with Ulcerative Colitis, Systemic Lupus Erythematosus and Psoriasis. 
Note that in some regions, such as 10p15.1, the conditional analysis supports the 
existence of multiple associated variants: if none of these overlap, then we consider 
the region to have separate SNP effects. Note we provide coordinates of the region, 
and not an index SNP as is conventional in gwas studies because the method 
synthesises information across the whole region and does not, in most cases, 
highlight a single SNP responsible for the association. 
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Chromosome  Position  Prior Associations  Associations Found  
Posterior probability 
both diseases are 
associated ℙ(ℍ3 or  
ℍ4)  
Posterior probability 
shared causal variant 
given joint 
association ℙ(ℍ4|ℍ3 
or  ℍ4) 
Candidate 
Causal Genes/ 
Genes in 
Region  
       
       
1q24.3  170882016–171208336  C  DC  DC:0.75  DC:0.95  FASLG  
       
2p14  65246601–65570598  R  RM  RM:0.86  RM:0.72  SPRED2  
       
2q11.2  99883120–100415547  DR  DRC  DC:0.98 RC:1.00  DC:0.57 RC:0.90  AFF3  
       
2q37.1  230758228–230962304  M  CM  CM:0.94  CM:0.90  SP140  
       
5q11.2  55450712–55492884  RM  DRM  DR:0.71 DM:0.71  DR:1.00 DM:1.00  ANKRD55  
       
6q23.3  137914792–138345363  RCM  DRC—M  DR:0.80 DC:0.77  DR:0.94 DC:0.93  TNFAIP3  
       
7p14.2  37323488–37406978  CM  RCM  RC:0.80 RM:0.77  RC:0.84 RM:0.83  ELMO1  
       
7p12.2  50222360–50335957  M  DM  DM:0.73  DM:0.70  
5’ IKZF1* 
region  
       
13q32.3  98723872–99034738  DM  D—C  DC:0.67  DC:0.00  GPR183  
       
15q25.1  76773859–77050416  DM  DC  DC:0.82  DC:0.99  CTSH  
       
19p13.2  10081000–11019034  DRM  DRM—C  
DC:0.87 RC:0.87 
CM:0.88  
DC:0.40 RC:0.46 
CM:0.57  
ICAM1 ICAM3 
TYK2  
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Table 3: Eleven regions showing strong evidence of novel association (ℙ(ℍ3 or  ℍ4) 
> 0.5) for an analysis involving a previously non–associated trait. D corresponds to 
T1D, R to RA, C to CEL and M to MS. Novel associations are underlined and 
denoted by bold font. Candidate causal genes are as associated across all curated 
diseases by ImmunoBase. Note that in the case of TNFAIP3, there is strong 
evidence that MS is caused by a distinct causal variant compared to the other traits. 
Distinct signals are separated by a ‘— ’. Since we only have a subset of the 
genotype data, not all of the prior (previously published) associations are seen. *An 
association of T1D in a region 3’ of IKZF1, for which it is hypothesised that IKZF1 is 
the candidate causal gene is already known33 (see Table 1). The novel association 
we report here is in a region 5’ of IKZF1, and independent of the established 
association. Note we provide coordinates of the region, and not an index SNP as is 
conventional in gwas studies because the method synthesises information across 
the whole region and does not, in most cases, highlight a single SNP responsible for 
the association. 
  
31 
 
  
 
Online Methods 
Samples 
All samples included in this analysis were gathered in the United Kingdom, and have 
reported or self declared European ancestry. Informed consent was obtained from all 
subjects. Detailed summaries of the sample cohorts are given in the ImmunoChip 
papers for CEL,17 RA,9 MS10 and T1D.30 For the RA and MS cases, we used the 
subset of cases from the UK. Sample exclusions were applied as described in each 
paper, and in total, 6,691 T1D, 3,870 RA, 7,987 CEL, 5,112 MS and 12,370 control 
samples were analyzed. SNPs were filtered according to the following criteria: call 
rate > 0.99; minor allele frequency > 0.01; Hardy–Weinberg |Z| < 5. SNPs which 
passed these thresholds in controls and any specific pair of cases were used for that 
pairwise analysis.  
Using only UK cases and controls means that we expect any effects of population 
stratification to be very limited, as evidenced by the low genomic inflation factors in 
published UK ImmunoChip analyses31 and we did not take any further specific 
actions to limit effects of population stratification.  
Selection of Regions for Analysis 
We considered all regions annotated in ImmunoBase (accessed on 12/11/13) as 
associated with at least one of our diseases. Where regions overlapped, we formed 
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the union. Regions containing fewer than ten SNPs or with a SNP density < 1 
SNP/kb were excluded. The MHC (chr6:29797978–33606563 hg18) was removed 
from the analysis, since this region is known to have complex multi–SNP effects. A 
full list of the 126 regions analyzed, together with our resulting associations, can be 
found in Supplementary Table 1.  
Colocalization Analysis 
Two colocalization methods were applied to each of the 126 regions (see 
Supplementary Fig. 1).  
Bayesian Approach  
The first approach is based upon a Bayesian approach proposed by 
Giambartolomei et al.5 All models in which each trait is caused by at most one 
variant are considered, and approximate Bayes factors computed for each. Our 
extension follows the same framework, but, in order to extend this method to the 
case of a common control, a multinomial model was used. Bayes factors were 
computed using a Laplace approximation32 as implemented in the R package 
mlogitBMA. Each of these models is contained within precisely one of the following 
sets:  
ℍ0: No SNP is associated with either trait 
ℍ1: There is a SNP associated with trait 2, but no SNP is associated with trait 1. 
ℍ2: There is a SNP associated with trait 1, but no SNP is associated with trait 2. 
ℍ3: Both the traits are associated with the region, with different causal variants. 
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ℍ4: Both the traits are associated with the region, and share a single causal 
variant. 
By summing the Bayes factors generated for all models in the set, a posterior 
possibility can be computed for each of the hypotheses, and hence for colocalization 
(ℍ4). Similarly, the posterior probability of any given model, given a specific 
hypothesis and equal prior probability of each model, is proportional to the Bayes 
factor for that model. Since a Bayes factor is assigned to each model independently, 
it is straightforward to calculate the conditional probability of each SNP being causal, 
given association, as proportional to the Bayes factor for the relevant model.  
This approach assumes a single causal variant at any region. In regions with 
strong evidence of association (ℙ(ℍ0) < 0.1) we performed conditional analysis. 
Firstly, all plausibly important SNPs were discovered by iteratively conditioning on 
the most likely set of SNPs to cause the associations seen, until there was no longer 
strong evidence of additional association. In those cases where multiple SNPs were 
considered relevant, all but a pair (one potentially causal for the first trait, and one for 
the second) were conditioned upon, in order to discover the colocalization (or not) of 
the effects at this pair alone.  
Proportional Approach  
A second method based upon the proportional approach2,3 was also used. 
Phenotypes are modeled using multinomial logistic regression, producing maximum 
likelihood estimates b1 and b2 of regression coefficients β1 and β2. Since the samples 
sizes can be large, the asymptotic normality of maximum likelihood estimators is 
used to approximate:  
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for some variance–covariance matrix V.  
The proportional method3 assumes that b1, b2 are independent (i.e. V 12 = V 21 = 
O). However in the extension to a common control dataset, we cannot assume this, 
and proceed with a fully unknown V.  
The null hypothesis corresponds to the existence of a constant η such that:  
𝛽𝛽1 = 1η 𝛽𝛽2 
Under this hypothesis, and given η,  
�β1 − 1
η
β2�𝑇𝑇 �V11 − 1ηV12 − 1ηV21 + 1η2 𝑉𝑉22�−1 �β1 − 1η β2�~𝜒𝜒𝑝𝑝2 
This is used as our test statistic. However, since the value of η was unknown, a 
posterior predictive p–value is generated instead, by integrating the p–values 
associated with the test statistic over the posterior distribution of η. To avoid bias in 
regression coefficients due to selection of SNPs on the basis of their strength of 
association, Bayesian model averaging was used to average inference over all 
plausible two SNP models.  
Further details of the colocalization methods can be found in the Supplementary 
Methods section.  
Identification of disease specific regions 
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To examine evidence for GWAS association with other traits, we took the index SNP 
with smallest p values in a region, and then identified proxy SNPs based on LD (r2 ≥ 
0.9) using 1000 genomes EUR data. We used this as a query SNP set to examine 
associations annotated in the NIHR GWAS catalog (accessed 07/10/2014)  
We identified disease specific regions for which: the posterior probability for 
single SNP association was >0.5; posterior probability of association with any other 
disease was <0.2; the region was not annotated as associated with any other 
autoimmune disease in ImmunoBase; and no proxies for the index SNP were 
associated with any other autoimmune disease in the NIHR GWAS catalog.  
Type 2 diabetes data 
Summary from a T2D GWAS meta–analysis22 was downloaded from the DIAGRAM 
website (accessed 20/10/14).  
Code availability 
The code used is given in the colocCommonControl R package, which can be found 
at  
https://github.com/mdfortune/colocCommonControl 
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